Merck & Co., Inc.
Financials
Valuation Metrics
Merck & Co., Inc.'s Market Cap is $366.53B. At end of 2025 it was $262.09B. Ranked #33 of 3,116 in US market (top 1%), #16 of 1,644 on NYSE (top 1.0%), #4 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $366.53B | US#33/3,116 Sec#4/265 |
| Revenue | $66.40B | US#88/3,116 Sec#3/265 |
| Net Income | $3.17B | US#231/3,116 Sec#14/265 |
| Total Assets | $129.80B | US#136/3,116 Sec#6/265 |
| Net Assets | $41.93B | US#104/3,116 Sec#6/265 |
| Employees | 73,000 | US#176/3,116 Sec#6/265 |
| Value | ||
| P/E | 115.52x | US#2,115/3,116 Sec#67/265 |
| P/B | 8.74x | US#2,551/3,116 Sec#187/265 |
| P/S | 5.52x | US#2,347/3,116 Sec#84/265 |
| EV/EBITDA | 29.88x | US#2,186/3,116 Sec#62/265 |
| FCF Yield | 4.38% | US#1,494/3,116 Sec#44/265 |
| Profitability | ||
| ROE | 7.57% | US#1,622/3,116 Sec#54/265 |
| ROA | 2.44% | US#1,530/3,116 Sec#60/265 |
| Op. Margin | 16.65% | US#1,090/3,116 Sec#47/265 |
| Revenue Growth | 4.24% | US#1,840/3,116 Sec#116/265 |
| Earnings Growth | -80.66% | US#1,803/3,116 Sec#50/265 |
| Financial Health | ||
| Debt Ratio | 209.42% | US#1,822/3,116 Sec#200/265 |
| Total Debt | $53.91B | US#82/3,116 Sec#5/265 |
| FCF | $16.06B | US#42/3,116 Sec#4/265 |
| Cash | $6.85B | US#153/3,116 Sec#8/265 |
| Current Ratio | 1.32x | US#1,855/3,116 Sec#245/265 |
| Net Debt/EBITDA | 3.40x | US#1,723/3,116 Sec#67/265 |
| Dividend | ||
| Div. Yield | 2.26% | US#828/3,116 Sec#14/265 |
| Div. Growth | 5.31% | US#791/3,116 Sec#8/265 |
| Performance | ||
| 1Y Return | 74.08% | US#302/3,116 Sec#56/265 |
| 1M Return | 2.84% | US#2,066/3,116 Sec#138/265 |
| From 52W High | -5.43% | US#614/3,116 Sec#41/265 |
| 1Y MDD | -11.90% | US#94/3,116 Sec#2/265 |
| Trading | ||
| Volume | 5,590,807 shares | US#183/3,116 Sec#11/265 |
| Trading Value | $831M | US#55/3,116 Sec#3/265 |
| Per Share | ||
| EPS | $1.28 | US#1,582/3,116 Sec#46/265 |
| BPS | $16.98 | US#1,412/3,116 Sec#43/265 |
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.